Cadila Healthcare is currently trading at Rs 688.95, up by 1.95 points or 0.28% from its previous closing of Rs 685.05 on the BSE.
The scrip opened at Rs 687.00 and has touched a high and low of Rs 690.00 and Rs 680.00 respectively.
The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 983.50 on 19-Jul-2011 and a 52 week low of Rs 642.95 on 23-Dec-2011.
Last one week high and low of the scrip stood at Rs 711.10 and Rs 677.35 respectively. The current market cap of the company is Rs 13986.37 crore.
The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 17.68% and 7.53% respectively.
Microbix Biosystems Inc., a biotechnology company commercializing novel technologies and Zydus Cadila , an Indian global pharmaceutical company have signed a letter of intent (LoI) to market the Thrombolytic drug, Urokinase in the North American markets.
The two companies expect a definitive agreement to be signed early in 2012, while the anticipated time-line for approval is late 2014. As per the terms of the agreement between both the companies, Zydus is required to provide the funding needed to re-launch the drug in the US and Canada, including an initial commitment, plus milestone based payments.
The estimated market size of the Urokinase use in the US alone is expected to touch $400 million by 2020 between three indications: pulmonary embolism, catheter clerarence and catheter prophylaxis.
Urokinase was acquired by Microbix in 2008 which has since then stepped up efforts to re-introduce the drug in North America.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1505.20 |
Dr. Reddys Lab | 5922.45 |
Cipla | 1339.45 |
Zydus Lifesciences | 983.05 |
Lupin | 1609.85 |
View more.. |